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Muscarinic receptor kinase activity previously described in intact CHO cells transfected with human m3-muscarinic receptor cDNA (CHO-m3 cells) 
[Tobin, A.B and Nahorski, S.R (1993) J. Biol. Chem. 268,9817-98231 was found to be associated, at least in part, with a crude membrane fraction 
of CHO-m3 cell lysates. Phosphorylation of the m3-muscarinic receptor was agonist dependent, reaching a maximum after 10 mitt exposure to 
carbachol (1 mM) and was completely blocked by atropine (10 PM). m3-Muscarinic receptor phosphorylation was insensitive to Zn2+ (0.1 mM) 
and heparin (1 &ml), concentrations that inhibit endogenous /%adrenergic receptor kinase activity present in CHO-m3 cells strongly suggesting 
that the m3-muscarinic receptor kinase is distinct from p-adrenergic receptor kinase. A role for protein kinase C can also be eliminated on the basis 
that the potent protein kinase C inhibitor, Ro-318220 (1 PM), had no effect on agonist-mediated m3-muscarinic receptor phosphorylation. Further, 
the inability of calcium (300 PM), CAMP (0.2 mM) and cGMP (0.2 mM) to elevate the basal phosphorylation state of m3-muscarinic receptors 
eliminates a role for protein kinases regulated by these second messengers. Finally, agonist mediated phosphorylation appears to be independent 
of G-protein activation as both GDP-B-S (500 PM) and GTP-1-S (100 PM) did not influence m3-muscarinic receptor phosphorylation. 
Muscarinic acetylcholine receptor; Muscarinic receptor kinase; Phosphoinositidase C; B-Adrenergic receptor kinase; Protein kinase C 
1. INTRODUCTION 
The muscarinic receptor gene family consists of five 
subtypes, three of which (ml, m3 and m5) are efficiently 
coupled to phosphoinositide hydrolysis via a pertussis 
toxin insensitive G-protein [l]. We have recently dem- 
onstrated that the phosphoinositidase C (PIG)-linked 
human m3-muscat-uric receptor expressed in transfected 
CHO cells (CHO-m3 cells) undergoes stoichiometric 
phosphorylation (-2 mol phosphate/m01 receptor), pri- 
marily on serine, following agonist activation [2]. Al- 
though the precise identity of the kinase involved was 
not determined by this earlier study it was possible to 
conclude that the m3-muscarinic receptor kinase was 
distinct from protein kinase C (PKC), Ca*+/calmodulin- 
dependent protein kinase and CAMP-dependent protein 
kinase (PKA) [2]. 
It is now clear that a number of G-protein linked 
receptors are phosphorylated in response to agonist oc- 
cupation. In the case of the cyclase-linked B-adrenocep- 
tor the role played by PKA and /3-adrenergic receptor 
kinase @-ARK) in uncoupling the /I-adrenoceptor from 
Gscl has been clearly delineated [3]. However, in vitro 
studies utilising reconstituted systems have demon- 
strated that B-ARK is also able to phosphorylate the 
cyclase linked mZmuscarinic [4,5] and a,-adrenergic 
receptors [6], and the PIClinked substance P receptor 
*Corresponding author. Fax: (44) (533) 52-3996. 
[7] suggesting that /?-ARK may be acting as a general 
G-protein receptor kinase with a wide substrate specific- 
ity [7]. 
Similarly, PKC is known to phosphorylate a number 
of G-protein linked receptors including the m2-muscar- 
inic receptor [8], 5-HT,, receptors [9], CCK receptor [lo] 
and qadrenoceptor [l 11. Furthermore, phorbol ester 
activation of PKC either diminishes [12] or completely 
abolishes [ 13,141 muscarinic receptor mediated 
phosphoinositide hydrolysis in cultured cell lines, indi- 
cating that PKC is able to influence the activity of at 
least one component of the muscarinic receptor signal 
transduction pathway although it is not clear that phos- 
phorylation of the receptor itself is involved. 
In the present study we establish that the kinase in- 
volved in m3-muscarinic receptor phosphorylation is 
associated with the particulate fraction and can be dis- 
tinguished from either B-ARK, PKC or other known 
second messenger regulated kinases. 
2. MATERIALS AND METHODS 
2.1. Materials 
Cell culture reagents were obtained from Gibco. [y-‘*P]ATP (3000 
Wmmol) was obtained from Amersham. All other reagents were 
obtained from Sigma. CHO cells transfected with recombinant human 
m3-muscarinic receptor cDNA (CHO-m3 cells, expression 
level = 1343 + 46 fmol/mg protein, [15]) were a kind gift from Dr. N.J. 
Buckley, National Institute for Medical Research, London, UK. De- 
tails of the antisera to the human m3-receptor have been previously 
published [2]. 
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2.2. Preparation of crude CHOICHO-m3 membrane fraction 
Non-transfected CHO or CHO-m3 cells were harvested and resus- 
pended in kinase buffer (20 mM Tris-HCl, 10 mM MgCl,, 10 mM 
NaCl, 1 mM EGTA, 2 mM DTT + protease inhibitors 1 mM PMSF, 
1 &ml leupeptin, 10 &ml soybean trypsin inhibitor and 10 @ml 
aprotinin), 4-6 flasks in 25 ml. Cells were disrupted by a 5 s pulse in 
an ultraturrax homogeniser (max. setting). Following ccntrifugation 
at 15,000 x g 10 min at 4°C the particulate membrane fraction was 
resuspended in kinase buffer to a concentration of 10 mg protein/ml. 
2.3. Phosphorylation ofm3-muscarinic receptors contained in CHO-m3 
membrane fractions 
CHO/CHO-m3 membranes (500 pg protein) resuspended in kinase 
buffer were incubated with 50 ,uM [Y-‘~P]ATP (14 dpm/fmol) for 10 
min at 30°C in the presence of various experimental gents. The tinal 
volume was 100 ~1. Reactions were stopped by a 30 s centrifugation 
in a microfuge, removal of the supematant, and solubilisation of 
m3-muscarinic receptors with 1 ml solubilisation buffer (10 mM Tris, 
10 mM EDTA, 500 mM NaCl, 1% NP-4O,O.l% SDS, 0.5% deoxycho- 
late + protease’s inhibitors). In the case of the time course the centrifu- 
gation step was omitted and the reaction terminated by direct addition 
of 1 ml of solubilisation buffer. Solubilised receptors were then im- 
munoprecipitated as described previously [2] and proteins resolved on 
8% SDS-PAGE. Following autoradiography gels were either sub- 
jected to densitometric analysis using a BioRad model GS 670 den- 
sitometer or radioactive bands were cut from the gel extracted in 
hyamine hydroxide and activity determined by scintillation counting. 
Stoichiometry of phosphorylation was calculated based on a recovery 
of m3-muscarinic receptors of _ 80% following immunoprecipitation 
(- 500 fmol receptor/assay, see [2]). 
2.4. Assay for protein kinase C activity 
Membranes from CHO-m3 cells were prepared either from unstim- 
ulated cells or, as a positive control, from CHO-m3 cells pretreated 
with PMA (100 nM, 10 min) to induce translocation of PKC to the 
plasma membrane [16]. The myelin basic protein fragment&,, 
QKRPSQRSKYL (25 pg/assay) was used as a substrate for PKC [ 171 
in an assay with CHO-m3 membranes (20&350 pug protein) in kinase 
buffer containing 50 PM [Y-~~P]ATP (100 dpm/pmol). In reactions 
utilising membranes from PMA pretreated cells the kinase assay was 
carried out in the presence of PMA (100 nM). The total reaction 
volume was 100 ~1. The reaction was initiated by addition of ATP and 
terminated by centrifugation at 13,000 x g for 5 min to sediment mem- 
branes. An aliquot of supematant (75 ~1) was placed on a square of 
Whatman P81 cellulose phosphate filter and washed 3 times with 75 
mM H,PO,, and once with ethanol before being subjected to liquid 
scintillation counting. 
inic receptor kinase activity (Fig. 1A). Incubation of 
CHO-m3 membranes with [Y-~‘P]ATP followed by im- 
munoprecipitation of m3-muscarinic receptors revealed 
that in the absence of agonist the m3-muscarinic recep- 
tor was phosphorylated. Inclusion of a maximal dose of 
the muscarinic agonist carbachol (1 mM) resulted in a 
dramatic increase in phosphorylation state of the m3- 
muscarinic receptor (Fig. lA), which was completely 
blocked by the muscarinic antagonist atropine (10 PM, 
Fig. 1 B). No m3-muscarinic receptor kinase activity was 
detected in cytoplasmic extracts from CHO-m3 cells nor 
from non-transfected CHO cells. In fact, addition of 
cytosolic extracts to CHO-m3 membranes decreased the 
level of agonist mediated phosphorylation (data not 
shown). Due to the likely presence of protein 
phosphatases in cytosolic preparations the possibility 
that the m3-muscarinic receptor kinase also exists in a 
soluble form cannot be eliminated. However, it is clear 
that at least a proportion of the m3-muscarinic receptor 
kinase is associated with the particulate fraction. These 
observations are not restricted to transfected CHO cells 
since preliminary studies on the human neuroblastoma 
cell line SH-SYSY, which express m3-muscarinic recep- 
tors at - 400 fmol/mg protein [21,22], have also identified 
a kinase that phosphorylates the agonist occupied m3- 
muscarinic receptor in a similar manner to that ob- 
served in CHO-m3 membranes (data not shown). 
Membrane phosphorylation of m3-muscarinic recep- 
tors peaks at 10 min agonist exposure (Fig. 2), where the 
stoichiometry is - 0. lmol phosphate/m01 receptor 
(n = 3), after which the m3-muscarinic receptor under- 
goes dephosphorylation. In contrast, phosphorylation 
of the m3-muscarinic receptor in intact CHO-m3 cells 
occurred within seconds of agonist occupation and was 
maintained for at least 30 mm, where the maximum 
B 0 
4 
2.5. Assay for B-ARK activity CCh(lmM) - + + + -+ + 
The activity of /I-ARK was determined essentially as described 
previously [18,19]. CHO-m3 cells were harvested and resuspended in 
twice the volume of kinase buffer. Cells were lysed by a 5 s pulse in 
an ultraturrax homogeniser (max setting) and a cytosolic extract pre- 
pared by centrifugation at 300,000 x g for 30 min (4°C). An aliquot 
of cytosolic extract (5 pg of protein) was mixed with urea-treated 
bovine rod outer segment membranes, (- 10 fig of protein prepared as 
described previously [20]) in kinase buffer containing 100 PM 
[y- j2P]ATP (- 270 dpm/pmol). The tinal volume was 20~1. The reaction 
was carried out at 30°C for 10 min and was terminated by addition 
of 20 ,~l SDS-PAGE sample buffer. Proteins were separated on a 12% 
SDS-PAGE gel. Following Coomassie blue staining and autoradio- 
graphy the band corresponding to rhodopsin was excised, protein 
extracted using hyamine hydroxide, and the radioactivity determined 
by liquid scintillation counting. 
3. RESULTS AND DISCUSSION 
A crude low speed (15,000 x g) membrane prepara- 
tion of CHO-m3 cells was found to contain m3-muscar- 
Fig. 1. Phosphorylation of m3-muscarinic receptors in the particulate 
fraction of CHO-m3 lysate. A: membrane preparations derived from 
either CHO-m3 cells or non transfected CHO cells were incubated in 
a buffer containing [Y-‘~P]ATP f 1 mM carbachol (CCh) for 10 min 
at 30°C. Following solubilisation, m3-muscarinic receptors were im- 
munoprecipitated with immune serum (I) or pre-immune serum (PI) 
antisera B. The effect of atropine (10 PM) on m3-muscarinic receptor 
phosphorylation. Positions of prestained molecular weight markers 
are indicated in kDa. 
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Fig. 2. Time course for m3-rnu~c receptor phospho~~ation i
CHO-m3 cell membranes. Legend as for Fig. 1. Data is representative 
of two determinations. Data was analysed by densitometry. 
stoi~hiome~y reached was - 2mol phosphate/m01 recep- 
tor. The difference between intact cells and membrane 
preparations may be attributable to factors missing in 
the membrane preparation that are necessary for effi- 
cient m3-muscarinic receptor phosphorylation, com- 
bined with rapidly falling ATP levels (during the first 10 
min the concentration of ATP in the kinase assay fell 
by 80%; n = 3) due to the presence of conta~nating 
ATPases. Application of okadaic acid (1 ,uM) to the 
membrane preparation enhanced agonist-mediated 
phosphorylation by - 5 fold (n = 2, data not shown) sug- 
gesting that deregulation of protein phosphatase activ- 
ity may also contribute to the low stoic~omet~ of 
phosphorylation. 
Alternatively, a proportion of the m3-muscarinic re- 
ceptor kinase may be cytoplasmic, therefore, providing 
an additional component of kinase activity in intact 
cells that would be missing in membrane preparations. 
It should be noted that early studies on partially puri- 
fied&ARK reported low levels offi-adrenoceptor phos- 
phorylation (0.2 mol phosphate/m01 receptor [23]) a sit- 
uation significantly improved by further purification of 
the kinase [24]. Similarly, we anticipate that purification 
of the m3-muscarinic receptor kinase will aliow for a 
precise dete~nation of its intra~ll~~ lo~alisation, 
and rate of in vitro phosphorylation together with an 
accurate measure of stoichiometry. 
The primary consequence of m3-muscarinic receptor 
activation in membrane preparations (preliminary re- 
sults indicate that there is a -Zfold increase in 
Ins( 1,4,5)P3 production in CHO-m3 membranes timu- 
lated by 1 mM carbachol under phosphorylating condi- 
tions) and intact CHO-m3 cells [15] is the hydrolysis of 
phosphoinositides resulting in the generation of inositol 
polyphosphates and the PKC activator, ~acylgly~rol. 
Thus a reasonable candidate for the kinase mediating 
phosphorylation of the m3-muscarinic receptor might 
be PKC. This, however, does not appear to be the case 
since the potent PKC inhibitor, RO-318220 [25], had no 
effect on ago~st-mediated m3-muscarinic receptor 
phospho~lation (Fig. 3). Fu~he~ore, since mem- 
branes were prepared from unstimulated cells it might 
be expected that levels of PKC activity associated with 
the membrane fraction would be low. This was found 
to be the case. In a PKC assay using a peptide pseudo- 
substrate, membranes prepared for the study of m3- 
muscarinic receptor phospho~lation had no detectable 
PKC activity (Fig. 4). However, in control membranes, 
where CHO-m3 cells had been pretreated with PMA 
(100 nM, for 10 min) to induce translocation of PKC 
to the plasma membrane [16], phosphorylation of the 
pseudo-substrate was readily detectable (Fig. 4). The 
absence of PKC in membrane preparations was further 
demonstrated by the ineffectiveness of PMA (100 nM) 
to induce m3-muscarinic receptor phosphorylation 
(data not shown). These data support that previously 
obtained in intact cells where agonist-mediated m3- 
mus~a~ni~ receptor phospho~lation was not affected 
by Ro-318220 at a concentration that completely sup- 
pressed phorbol ester-induced phosphorylation [2]. 
Hence the data presented here and previously [2] con- 
clude that the agonist-mediated m3-muscarinic receptor 
kinase is distinct from PKC. 
The involvement of other second messenger activated 
protein kinases, PKA, cGMP-dependent protein kinase 
and Ca”/calmodulin dependent protein kinase can be 
eliminated on the basis of the lack of kinase activity 
detected following the application of CAMP (0.2 mM), 
cGMP (0.2 mM) and Ca2’ (final concentration = C300 
PM), respectively (Figure 3). Indeed, elevated [Ca”] 
Fig. 3. Characterisation of the m3-muscarinic receptor kinase. A: the 
effect of ZnCl, (0.1 mM), NaCl (110 mM), Na-citrate (20 mM) and 
CaCl, (300 PM) on carbachol (CCh, 1 mM) mediated m3-muscarinic 
receptor phospho~~tion. B: the effect of Ro-318220 (1 PM) and 
heparin (1 @ml} on agonist mediated m3-rnu~a~c receptor phos- 
phoryiation and the effect of calcium (300 pM), CAMP (0.2 mM) and 
cGMP (0.2 mM) on basal m3-muscarinic receptor phosphorylation. 
Data are representative of 2-3 independent determinations with each 
reagent. 
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Fig. 4. PKC activity associated with CHO-m3 membrane prepara- 
tions. CHO-m3 membranes were either prepared from non-treated 
cells, or as a positive control, from cells pre-treated with PMA (100 
nM, 10 min) to induce translocation of PKC to the plasma membrane. 
PKC activity was then assayed as described in the text using 25 @g/ 
assay of myelin basic protein fragment+,, (MPB). Results are the 
mean k standard error of 3 experiments carried out in triplicate. 
decreased the level of agonist driven phospho~lation 
(Fig. 3). Whether this is a direct effect on the receptor 
kinase or activation of calcium-sensitive phosphatases 
has yet to be determined but may be important in the 
regulation of m3-muscarinic receptor phosphorylation 
in the intact cell where m3-mu~a~nic receptor activa- 
tion results in elevated intra~ll~ar calcium concentra- 
tions [ 151. 
In vitro studies have established that /?-ARK, in addi- 
tion to acting on j?-adrenoceptors, is also able to phos- 
phorylate a number of other cyclase-linked receptors 
including mZmuscarinic receptors [4,5] and a,-adreno- 
ceptors [6]. Further, an m2-muscarinic receptor kinase, 
recently purified from the porcine cerebrum, possesses 
properties nearly identical to B-ARK suggesting that 
one or more of the members of the/&ARK family is able 
to phosphorylate mZmuscarinic receptors in an ag- 
onist-de~ndent manner [26,27]. The substrate specific- 
ity of B-ARK may not, however, be limited to receptors 
coupled to cyclase. A recent study demonstrating that 
B-ARK is able to phosphorylate the PIClinked sub- 
stance P receptor in a reconstituted receptor/Gq-pro- 
tein@-ARK lipid system [7] has led to the proposal that 
@-ARK may be a general G-protein receptor kinase [7]. 
It is clear, however, from the present study that @- 
ARK is unlikely to be the kinase involved in agonist- 
mediated phosphorylation of m3-muscarinic receptors 
in CHO-m3 membranes. Despite showing sensitivity to 
high concentrations of sodium chloride (110 mM) and 
sodium citrate (20 mM; Fig. 3), properties shared with 
/LARK [24], 3 m -muscarinic receptor phosphorylation 
is unaffected by 50 ,uM Zn2’ (data not shown) and 100 
PM Zn2+ (Fig. 3), concentrations hown previously to 
reduce purified P-ARK activity to 55% and 6% of con- 
trols, respectively [24]. Furthermore, heparin (4000- 
6000 MW) at 1 ,&ml had no inhibitory effect on m3- 
muscarinic receptor phosphorylation (Fig. 3). This con- 
centration of heparin has previously been shown to 
completely inhibit B-ARK activity in permeabilised 
A431 cells [28] and to reduce the phospho~lation of 
rhodopsin by purified /I-ARK [29] and the phosphoryl- 
ation of mZmuscarinic receptors by a /&ARK related 
kinase [27] to 20-25% of controls. m3-Muscarinic recep- 
tor phosphorylation in our system is, however, partially 
inhibited by heparin at 10 &ml (data not shown). As 
an internal control, @-ARK was assayed in CHO-m3 
cytosolic extracts using rhodopsin as a substrate. In 
agreement with a previous report [19] low levels of en- 
dogenous B-ARK activity were detected in CHO-m3 
cytoplasmic extracts (“9 pmol of phosphate incorpo- 
ratedlmg cytosolic protei~minute (n = 5)). In the pres- 
ence of 1 &$nl heparin or SO ,uM Zn”, conditions that 
had no effect on m3-muscarinic receptor phosphoryla- 
tion, endogenous /?-ARK activity was reduced by 82% 
and 81%, respectively (n = 4). Therefore, since the m3- 
receptor kinase is at least partly particulate and insensi- 
tive to inhibition by Zn2’ and heparin at concentrations 
that inhibit endogenous /?-ARK activity it would seem 
likely that this kinase is distinct from B-ARK. 
Stimulation of the signal transduction pathway cou- 
pled to m3-muscarinic receptors does not appear to be 
a prerequisite to receptor phosphorylation since GDP- 
&S (500 PM) which prevents receptor-mediated G-pro- 
tein activation 130,311 had no inhibitor effect on m3- 
receptor phosphorylation (n = 3). Furthermore, GTP- 
y- S (100 ,uM) shown previously to enhance m3-muscar- 
inic receptor mediated phosphoinositide hydrolysis and 
calcium mobilisation in permeabilised SH-SYSY cells 
[3 1] and to augment agonist mediated Ins( I ,4,5)P3 pro- 
duction in CHO-m3 membranes (Tobin, Keys and 
Nahorski, unpublished ata), had no effect on the basal 
state of the m3-muscarinic receptor phosphorylation 
(n = 3) nor any effect on agonist-mediated phosphoryla- 
tion (n I= 3). An alternative mechanism for m3-muscar- 
inic receptor phospho~lation is that the kinase is con- 
stitutively active and that a confo~ational change in 
the receptor induced by agonist occupation ‘opens’ 
phosphorylation sites which previously were protected 
from the receptor kinase. Although activation of the 
mZmuscarinic receptor kinase via a mechanism de- 
pendent of G-proteins cannot be completely ruled out 
evidence in support for a constitutively active kinase has 
been obtained from a preliminary study where a frag- 
ment of the m3-muscarinic receptor was phosphory- 
lated by CHO-m3 membranes in an agonist- independ- 
ent manner. 
Drawing primarily from work on the /I-adrenoceptorl 
adenylate cyclase system, receptor phospho~lation is 
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considered to be a general process mediating a reduc- 
tion in receptor responsiveness or desensitisation [3]. 
Analysis of m3-muscarinic receptor mediated total inos- 
itol phosphoinositide hydrolysis and Ins( 1,4,5)P3 pro- 
duction in the first 60 s of agonist stimulation has re- 
vealed that the m3-muscarinic receptor phosphoinosi- 
tide response undergoes rapid partial desensitisation 
[15,32]. Furthermore, a short 5 min pre-exposure of 
CHO-m3 cells to carbachol reduces the phosphoinosi- 
tide and calcium mobilisation responses to a subsequent 
application of agonist [ 151. These desensitisation events 
correlate temporally with phosphorylation of m3-mus- 
carinic receptors in intact cells [2] and suggest hat the 
two processes could be connected. Understanding the 
nature of the kinase involved in m3-muscarinic receptor 
phosphorylation provides valuable information neces- 
sary to determine the functional significance of m3- 
muscarinic receptor phosphorylation and any possible 
role this process may have in receptor desensitisation. 
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